TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT01876251

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.”

The sponsor’s own words in the registry.

Life of this trial

20132014201520162017201820192020Registered2013-06-10Started2013-11-04Stopped2015-12-24Results posted2019-03-15

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
Pfizer
Sponsor type
Industry
Conditions
Breast Cancer Metastatic
Interventions
PF-03084014; PF-03084014; PF-03084014; Docetaxel; Docetaxel
Participants
30
Sites
16
Countries
Belgium, Italy, Spain, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.